TABLE 2.
Comparison of Baseline Disease Characteristics and Laboratory Tests Between Pre-infliximab OSMlow (<143.5 pg/mL) and OSMhigh
| Baseline Characteristics | OSMlow (n = 23) | OSMhigh (n = 17) | P |
|---|---|---|---|
| Age at start of infliximab, y (mean, SD) | 13.6 (3.7) | 12.8 (4.7) | 0.57 |
| Time with Crohn, d (median, IQR) | 65 (25–226) | 35 (14–280) | 0.50 |
| BMI z-score (mean, SD) | −1.0 (1.2) | −0.24 (1.1) | 0.041 |
| Surgery before anti-TNF, n (%) | 2 (8.7%) | 0 | 0.50 |
| Starting infliximab dose, mg/kg (median, IQR) | 5.9 (5–6.8) | 6.3 (5.8–9.2) | 0.08 |
| wPCDAI (median, IQR) | 40 (20–60) | 40 (18–74) | 0.59 |
| CRP, mg/dL (median, IQR) | 0.71 (0.28–1.6) | 1.4 (0.95–3.4) | 0.062 |
| Albumin, g/dL (mean, SD) | 3.4 (0.4) | 3.3 (0.5) | 0.21 |
| Fecal calprotectin, µg/g (median, IQR) | 1383 (743–2501) | 1656 (817–2501) | 0.38 |
BMI, body mass index; CRP, c-reactive protein.